



福萊特玻璃集團股份有限公司

Flat Glass Group Co., Ltd.

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6865)

THIRD QUARTERLY REPORT
FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2022

1. IMPORTANT NOTICE

Figure 1. The proposed model for the development of the *Staphylococcus aureus* infection in the skin of the patient with the skin disease. The patient with the skin disease is exposed to the *Staphylococcus aureus* bacteria. The bacteria enter the skin through the wound and cause the infection. The infection is characterized by the presence of the bacteria in the skin, the formation of the abscess, and the development of the cellulitis. The infection is treated with antibiotics and surgical debridement. The patient is monitored for the development of the infection and the treatment is adjusted accordingly.

[illegible]

• **Prevalence** = the proportion of a population that has a disease at a particular point in time

2. KEY FINANCIALS

2.1 Major financial statements items and financial indicators

$$-U_{\theta, \gamma} - M$$

For the
three months
from 1 July

Items

[illegible]

4. QUARTERLY FINANCIAL STATEMENTS

4.1 Financial Statements

Consolidated Balance Sheet

As at 30 September 2022

Items	As at 30 September 2022	As at 31 December 2021
Current assets:		
Trade receivables	1,000,000.00	1,000,000.00
Trade payables	(500,000.00)	(500,000.00)
Prepaid expenses	200,000.00	200,000.00
Other current assets	300,000.00	300,000.00
Non-current assets:		
Property, plant and equipment	1,500,000.00	1,500,000.00
Intangible assets	500,000.00	500,000.00
Other non-current assets	100,000.00	100,000.00
Total assets	2,300,000.00	2,300,000.00

Items	As at 30 September 2022	As at 31 December 2021
Current liabilities:		
Trade payables	0,000.00	0,000.00
Other payables	0,000.00	0,000.00
Accruals	0,000.00	0,000.00
Provisions	0,000.00	0,000.00
Current tax liabilities	0,000.00	0,000.00
Current interest liabilities	0,000.00	0,000.00
Current loan liabilities	0,000.00	0,000.00
Current lease liabilities	0,000.00	0,000.00
Current pension liabilities	0,000.00	0,000.00
Current derivative liabilities	0,000.00	0,000.00
Current contingent liabilities	0,000.00	0,000.00
Current other liabilities	0,000.00	0,000.00
Non-current liabilities:		
Long-term debt	0,000,000.00	0,000,000.00
Long-term lease liabilities	0,000,000.00	0,000,000.00
Long-term pension liabilities	0,000,000.00	0,000,000.00
Long-term contingent liabilities	0,000,000.00	0,000,000.00
Long-term other liabilities	0,000,000.00	0,000,000.00
Owner's equity:		
Share capital	0,000,000.00	0,000,000.00
Reserves	0,000,000.00	0,000,000.00
Retained earnings	0,000,000.00	0,000,000.00
Other reserves	0,000,000.00	0,000,000.00
Share premium	0,000,000.00	0,000,000.00
Other equity	0,000,000.00	0,000,000.00
Total	0,000,000.00	0,000,000.00

For the nine months ended 30 September 2022

Items	For the nine months ended 30 September 2022	For the nine months ended 30 September 2021
I. Total operating income	1,000,000	1,000,000
Operating income	1,000,000	1,000,000
II. Total operating costs	(1,000,000)	(1,000,000)
Operating costs	(1,000,000)	(1,000,000)
III. Operating profit (loss expressed with "-")	0	0
Operating profit	0	0
IV. Total profit (total loss expressed with "-")	0	0
Total profit	0	0

Items	For the nine months ended 30 September 2022	For the nine months ended 30 September 2021
V. Net profit (net loss expressed with “-”)	, 0 , , 0.	, , ,0 0.
()		
N		
(-)	, 0 , , 0.	, , ,0 0.
()		
N		
(-)	, 0 , , 0.	, , ,0 0.
VI. Other comprehensive income, net of tax	0, 0 , .	, , , .0
() N		
	0, 0 , .	, , , .0
		, , , .0
(-)		, , , .0
	0, 0 , .	, , , .
(-)	, , , 0	0, , .
	, , , 0	
VII. Total comprehensive income	, , 0 , .	, , 0 , .
()		
	, , 0 , .	, , 0 , .
VIII. Earnings per share		
()	0. 0	0. 0
()	0. \	0. 0

M 0, M 0.

H J W

I H

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains.

For the nine months ended 30 September 2022	For the nine months ended 30 September 2021
---	---

Figure 1. The effect of the number of trials on the number of correct responses. The number of correct responses was significantly higher than the number of incorrect responses in all cases.

II. Cash flow from investing activities

	00,000,000.00	,0 0,000,000.00
N	, 00, \ .0	, , , .
	, 0, 0.0	, , , .
	, , , .	, , , \ .
	,00 , .	, , 0 , .
	, \ 0, , , \ .	, 0, , , .
	0 , 00,000.00	,0 0,000,000.00
N	, 0 , , , 0.	
	, , , .	, \ , , . 0
	, , 0 ,0 .	,0 , , 0 .
N	, 0,0 , , , \ .	- , 0 , , , .

